CGEN — Compugen Ltd.

Compugen (CGEN) Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Cash Position: As of March 31, 2026, Compugen reported approximately $134.9 million in cash, cash equivalents, and marketable securities.
• Revenue: Q1 2026 revenues were approximately $2.2 million, slightly down from $2.3 million in Q1 2025, primarily reflecting milestone payments from Gilead.
• Expenses: R&D expenses increased to $6.9 million from $5.8 million in the prior year, attributed to costs associated with the MAIA-ovarian trial and drug supply. G&A expenses were stable at $2.3 million.
• Net Loss: The net loss for Q1 2026 was approximately $7.7 million or $0.08 per share, compared to a net loss of $7.2 million or $0.08 per share in Q1 2025.

2. Strategic Updates and Business Highlights

• COM701 Development: The company is advancing its COM701 program, targeting PVRIG for ovarian cancer treatment. A new adaptive trial, MAIA-ovarian, has been initiated to test COM701 as maintenance therapy in relapsed platinum-sensitive ovarian cancer.
• Partnership with AstraZeneca: Compugen expressed confidence in the Rilvegostomig (Rilve) program, highlighting AstraZeneca's recent presentations at the AACR Annual Meeting and the potential for significant revenue from this partnership.
• GS-0321 Progress: The Phase I trial for GS-0321, an anti-IL-18 binding protein antibody licensed to Gilead, is ongoing. Compugen has received $90 million to date and is eligible for up to $758 million in additional milestone payments.

3. Forward Guidance and Outlook

• The company expects its cash runway to extend into 2029, allowing continued investment in clinical trials and early-stage pipeline development.
• The MAIA-ovarian trial is on track for interim analysis data by Q1 2027, which could inform future clinical strategies.

4. Challenges and Points of Concern

• Revenue Decline: The slight decrease in revenue year-over-year may indicate challenges in monetizing assets or slower-than-expected progress in partnerships.
• Clinical Trial Risks: The success of COM701 in the MAIA-ovarian trial is uncertain, particularly given the exploratory nature of the trial and the benchmarks for progression-free survival (PFS) that need to be met.
• Market Competition: Compugen faces competitive pressures in the immuno-oncology space, particularly regarding the efficacy and market acceptance of its therapies compared to existing treatments.

5. Notable Q&A Insights

• MAIA-Ovarian Trial: The trial is not stratified by PD-L1 status but by treatment line. The interim analysis will assess the potential for adding arms based on data outcomes.
• Enrollment Status: While specific enrollment numbers were not disclosed, the company is confident in meeting its timeline for the interim analysis.
• Benchmarking: The control arm's PFS benchmark is approximately 5.5 months, with the company aiming for a 3-month improvement to demonstrate meaningful clinical activity.

This summary encapsulates the key aspects of Compugen's Q1 2026 earnings call, highlighting both the company's strategic initiatives and the financial metrics that define its current standing and future outlook.